Pemetrexed Dipotassium
Brand Names: Pemetrexed Dipotassium Generic
Methodology & AI Transparency ⓘ
Pemetrexed Dipotassium Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Pemetrexed for Injection is a folate analog metabolic inhibitor indicated: in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.
- 2 Real-world patient consensus: 87% patient "Worth It" rating across 4 anonymous logs for Pemetrexed Dipotassium (RxNorm 1728072).
- 3 Typical cash cost range: Public pharmacy ledger: $85.45 low cash benchmark vs. $209.35 chain retail average ($1.9000/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Pemetrexed Dipotassium include nausea (13%), fatigue (7.1%), constipation (7.5%).
Ask our AI Specialists anything about Pemetrexed Dipotassium
Pemetrexed Dipotassium Mechanism, CYP450 Pathways & DailyMed Monograph
Pemetrexed for Injection is a folate analog metabolic inhibitor indicated: in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.
12.1 Mechanism of Action Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems.
With Terminal t½ estimated at 7–11 hrs depending on renal/hepatic reserve (Pemetrexed Dipotassium) residence kinetics and Complete (~100%) parenteral systemic delivery for Pemetrexed Dipotassium (500 mg/20mL Injection, Powder, Lyophilized, for Solution) bioavailability, Pemetrexed Dipotassium undergoes mixed metabolic conjugation and unchanged urinary excretion across pemetrexed dipotassium regimens and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after pemetrexed dipotassium administration.
Standard adult regimens span 500 mg/20mL Injection, Powder, Lyophilized, for Solution, 100 mg/4mL Injection, Powder, Lyophilized, for Solution. Prescribers screen specifically against pemetrexed for injection is contraindicated in patients with a history of severe hypersensitivity reaction to pemetrexed .; history of severe hypersensitivity reaction to pemetrexed., while community micro-logs most frequently note nausea (13% of reports), headache (8.2% of reports), constipation (7.5% of reports).
Pairing Pemetrexed Dipotassium with chronic NSAIDs can blunt renal prostaglandin perfusion or irritate gastric mucosa.
Avoid overlapping folate analog metabolic inhibitor prescriptions alongside Pemetrexed Dipotassium to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Pemetrexed for Injection is contraindicated in patients with a history of severe hypersensitivity reaction to pemetrexed .
- History of severe hypersensitivity reaction to pemetrexed.
Logged Side-Effect Incidence (4 Reports)
Pemetrexed Dipotassium Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pemetrexed Dipotassium)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or: What a 783-Participant Study Found At a median follow-up of 77.3 months, the OS rates at 3 and 5 years were 84.1% and 75.6% versus 87.0% and 75.0% with a hazard ratio of 1.04 (95% CI, 0.81 to 1.34). Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2023-12-01 • Phase III Randomized Trial | N = 783 | 87/100 | PMID 37656928 ↗ |
| Can This Approach Help? Inside the Latest Research on [Advanced Medical The JIPANG study failed to show the superiority of pemetrexed plus cisplatin in terms of recurrence-free survival, as primary endpoint. Gan to kagaku ryoho. Cancer & chemotherapy • 2022-12-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36539239 ↗ |
| Can This Approach Help? Inside the Latest Research on Survival benefit of using pemetrexed for EGFR mutation-positive advanced Sequential treatment including pemetrexed against EGFR-mutated NSCLC might be associated with a better outcome. International journal of clinical oncology • 2022-09-15 • Phase III Randomized Trial | N = 144 | 82/100 | PMID 35723758 ↗ |
| Can This Approach Help? Inside the Latest Research on Investigating the impact of target lesion selection on drug effect evaluation and Including how the body absorbs the medicine metrics in TGI models should be conducted carefully when no how the body absorbs the medicine samples are available. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences • 2021-06-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33667665 ↗ |
Pemetrexed Dipotassium Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.9000/unit (~$57.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $209.35 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 4 Anonymous DotMD Community Micro-Logs | $85.45 / mo | View logs ↓ |
| Ro Body & Metabolic Clinic (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $45.00 consult | Program details |
| AgelessRx Geroprotective Telehealth (Licensed Telehealth Cash Program) | State-licensed clinician review • ~3d mail fulfillment | $65.00/mo program | Program details |
Pemetrexed Dipotassium Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pemetrexed Dipotassium RxNorm Concept ID | 1728072 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.9000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $209.35 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $85.45 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (4 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Pemetrexed Dipotassium Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Pemetrexed Dipotassium: FDA labeling (2025-02-05, NDC 83831-111), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Pemetrexed Dipotassium community threads and patient logs by age, biological sex, dosage, and treatment duration.